Atropos Health Secures $33M Series B to Advance Generative AI in Healthcare

Share This Post

Key Highlights

  • $33 million Series B funding led by Valtruis with participation from strategic investors.
  • Adoption of Generative AI platform (GENEVA OS™) by key healthcare institutions.
  • Expansion of Atropos Evidence™ Network in oncology and specialty care.
  • Launch of ChatRWD to produce real-world evidence in minutes.
  • Mike Spadafore joins the board to advance value-based care initiatives.

Source: Business Wire

Notable Quotes

  • “As leading industry players increasingly recognize the value of having the right data, rather than just having the most data, Atropos Health stands out in its ability to understand and score datasets in a compliant and secure manner in order to accelerate research and improve patient outcomes.” Michelle Snyder, Partner at McKesson Ventures
  • “Atropos Health is built on investment in scaling the production of high-quality, transparent, and now real-time evidence production that matches the standards of the clinical and research communities.”  Brigham Hyde, CEO and Co-Founder at Atropos Health
  • “Atropos Health has the potential to dramatically improve existing workflows across both life sciences and health systems, in turn improving clinician decision-making and driving better outcomes for patients.”  Mike Spadafore, Managing Director at Valtruis

SoHC's Take

Atropos Health’s recent $33 million Series B funding round marks a significant milestone in the integration of Generative AI within the healthcare industry. The backing by prominent investors like Valtruis, McKesson Ventures, and Merck Global Health Innovation Fund underscores the critical role of high-quality, real-world evidence in advancing patient care and research. The adoption of Atropos Health’s GENEVA OS™ platform by major healthcare and life sciences institutions highlights the increasing demand for accurate, timely, and compliant data solutions. With innovative tools like ChatRWD™, Atropos Health is poised to revolutionize the production of real-world evidence, enhancing decision-making processes and driving value-based care across the healthcare ecosystem.

More To Explore

Total
0
Share